HOSPITAL UNIVERSITARIO RUBER

2018

1. CXCR4 antagonists for treatment of breast cancer

   Oncotarget

2. Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology

   Revista Espanola de Patologia

3. Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology (Clinical and Translational Oncology, (2018), 20, 7, (815-826), 10.1007/s12094-017-1800-5)

   Clinical and Translational Oncology

4. Corrigendum: Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: A proof-of-principle (Annals of Oncology (2014) 25 (1729–1735) DOI: 10.1093/annonc/mdu239)

   Annals of Oncology

5. Corrigendum: Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab [Ann Oncol., 28, (2017) (761-768)] DOI: 10.1093/annonc/mdw695

   Annals of Oncology

6. Erratum to: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer (Nature Cell Biology, (2018), 20, 2, (211-221), 10.1038/s41556-017-0021-z)

   Nature Cell Biology

7. Erratum: PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer (Science Translational Medicine DOI: 10.1126/scitranslmed.aaa4442)

   Science Translational Medicine

8. Reply to K.S. Shohdy et al

   Journal of Clinical Oncology

9. The new world of biosimilars in oncology: Translation of data to the clinic

   European Journal of Cancer